{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:17Z","timestamp":1790267057845,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biohaven Pharmaceuticals, Inc. which was acquired by Pfizer in October 2022."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rimegepant is an oral, small molecule calcitonin gene-related peptide receptor antagonist for acute treatment of migraine and migraine prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-site, placebo-controlled, sequential, single and multiple ascending dose study in healthy males and females, aged 18\u201355 years, with no clinically significant medical history. The objectives were to assess the safety, tolerability, and pharmacokinetics of the oral capsule free-base formulation. Single oral doses of rimegepant from 25\u20131500\u2009mg were evaluated in the single ascending dose phase, and 75\u2013600\u2009mg\/day doses administered for 14 days were evaluated in the multiple ascending dose phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No dose-related trends were observed in orthostatic systolic and diastolic blood pressure or heart rate after rimegepant administration. Rimegepant was rapidly absorbed with the median time of maximum observed plasma concentration from 1\u20133.5 hours. Rimegepant showed a more than dose-proportional increase in exposure from 25\u20131500\u2009mg following a single dose and from 75\u2013600\u2009mg\/day following multiple doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rimegepant was safe and generally well tolerated at single oral doses up to 1500\u2009mg and multiple doses up to 600\u2009mg\/day for 14 days in healthy participants in this study. Median terminal half-life ranged from 8\u201312 hours across the wide range of single doses studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024231179131","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T03:04:56Z","timestamp":1686107096000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants"],"prefix":"10.1177","volume":"43","author":[{"given":"Richard","family":"Bertz","sequence":"first","affiliation":[{"name":"Biohaven Pharmaceuticals Inc., New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajinder","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Certara USA, Princeton, NJ, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Morris","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals Inc., New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ashbrenner","sequence":"additional","affiliation":[{"name":"Navitas Data Sciences, Pottstown, PA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Coric","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals Inc., New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Croop","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals Inc., New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"bibr1-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr2-03331024231179131","first-page":"S23","volume":"25","author":"Peters GL.","year":"2019","journal-title":"Am J Manag Care"},{"key":"bibr3-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32160-7"},{"key":"bibr4-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00196-2"},{"key":"bibr5-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"bibr6-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"bibr7-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"bibr8-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"bibr9-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"bibr10-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"bibr11-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"bibr12-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"bibr13-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008944"},{"key":"bibr14-03331024231179131","first-page":"189","volume":"39","author":"Lipton RB","year":"2019","journal-title":"Cephalalgia"},{"key":"bibr15-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020954800"},{"key":"bibr16-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1895749"},{"key":"bibr17-03331024231179131","doi-asserted-by":"publisher","DOI":"10.2174\/138920010791636185"},{"key":"bibr18-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1002\/pst.326"},{"key":"bibr19-03331024231179131","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01810"},{"key":"bibr20-03331024231179131","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121180"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231179131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024231179131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231179131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:54Z","timestamp":1777387554000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024231179131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/03331024231179131"],"URL":"https:\/\/doi.org\/10.1177\/03331024231179131","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"article-number":"03331024231179131"}}